Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 20/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL985971 | 0.90 | ELANE (0.83) | ELANECYP2C9CYP3A4 | |
| SCHEMBL17378390 | 0.90 | ELANE (0.83) | ELANECYP2C9CYP3A4 | |
| SCHEMBL18879434 | 0.89 | ELANE (0.82) | ELANECYP2C9CYP3A4 | |
| SCHEMBL27888247 | 0.88 | ELANE (0.80) | ELANECYP2C9CYP3A4 | |
| SCHEMBL2273394 | 0.87 | ELANE (1.00) | ELANECYP2C9 | |
| SCHEMBL14922185 | 0.86 | ELANE (0.81) | ELANE | |
| SCHEMBL14922184 | 0.86 | ELANE (0.80) | ELANE | |
| SCHEMBL27872087 | 0.85 | ELANE (0.82) | ELANE | |
| SCHEMBL987063 | 0.85 | ELANE (0.82) | ELANE | |
| SCHEMBL1604508 | 0.85 | ELANE (0.81) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150588-B2 | Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9150588-B2 | Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20130137675-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-30 | — | — | US | disclosed |
| US-20130137675-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-30 | — | — | US | disclosed |
| US-8436024-B2 | 2-pyridone compounds | ASTRAZENECA AB (GB) | 2013-05-07 | — | — | US | disclosed |
| US-8436024-B2 | 2-pyridone compounds | ASTRAZENECA AB (GB) | 2013-05-07 | — | — | US | disclosed |
| US-8436024-B2 | 2-pyridone compounds | ASTRAZENECA AB (GB) | 2013-05-07 | — | — | US | disclosed |
| WO-2011039528-A1 | 2-PYRIDONE COMPOUNDS USED AS INHIBITORS OF NEUTROPHIL ELASTASE | ASTRAZENECA AB (SE) | 2011-04-07 | — | — | WO | disclosed |
| US-20110082155-A1 | Novel 2-Pyridone Compounds | ASTRAZENECA AB (SE) | 2011-04-07 | — | — | US | disclosed |
| US-20110082155-A1 | Novel 2-Pyridone Compounds | ASTRAZENECA AB (SE) | 2011-04-07 | — | — | US | disclosed |
| US-20110082155-A1 | Novel 2-Pyridone Compounds | ASTRAZENECA AB (SE) | 2011-04-07 | — | — | US | disclosed |
| US-20110003858-A1 | MULTIMERIC HETEROCYCLIC COMPOUNDS USEFUL AS NEUTROPHIL ELASTASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082155-A1 | Novel 2-Pyridone Compounds | SERPINB1, ELANE, EPX | ELANE 2/4885CYP2C9 868/4885CYP3A4 351/4885 |
| US-20130137675-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | PDE3A, PDE2A, PDE5A | ELANE 1517/4885CYP2C9 487/4885CYP3A4 783/4885 |
| US-20110003858-A1 | MULTIMERIC HETEROCYCLIC COMPOUNDS USEFUL AS NEUTROPHIL ELASTASE INHIBITORS | SERPINB1, ELANE, MPO | ELANE 2/4885CYP2C9 536/4885CYP3A4 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.